MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) has announced the appointment of Tyler Reinheimer, CPA, as Director, Finance, effective September 3, 2026, alongside a board-approved grant of 1,126,954 deferred share units (DSUs) to eligible directors and Mr. Reinheimer. The DSUs were issued under the company's omnibus equity incentive plan, representing a notable addition to MustGrow's executive compensation structure. Investors in the Saskatoon-based biological agriculture company may be watching how this leadership addition supports the company's ongoing commercialisation efforts.

Key Points

  • MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) is a Saskatoon-based biological agriculture company.
  • Tyler Reinheimer, CPA, has been appointed Director, Finance, effective September 3, 2026.
  • A total of 1,126,954 DSUs were granted to eligible directors (excluding the CEO and COO) and Mr. Reinheimer under the company's omnibus equity incentive plan.
  • Investors may be watching how the new finance leadership aligns with MustGrow's commercialisation and intellectual property expansion strategy.

Tyler Reinheimer Joins MustGrow as Director, Finance

MustGrow Biologics announced on September 4, 2026, that Tyler Reinheimer, CPA, has been appointed to the role of Director, Finance. The appointment became effective September 3, 2026, according to the company's release. MustGrow did not disclose further biographical details about Mr. Reinheimer's professional background in the announcement. The addition of a designated finance director may signal an effort to strengthen internal financial oversight as the company pursues broader commercialisation of its biological agriculture portfolio, which includes products registered and sold in key U.S. agricultural states including California.

Structure and Vesting Conditions of the DSU Grant

The board of directors authorised a total of 1,126,954 DSUs, granted to directors — excluding the Chief Executive Officer and Chief Operating Officer — and to Mr. Reinheimer. The DSUs were granted pursuant to the company's omnibus equity incentive plan and carry a deferred vesting structure: they vest only when the holder ceases to be a director, officer, or employee of MustGrow or any of its affiliates. Upon settlement, each DSU entitles the holder to one common share in the company's capital, or a cash equivalent at MustGrow's discretion.

MustGrow's Biological Agriculture Platform and Share Capital

MustGrow centres its technology on organic compounds derived from mustard seed, formulated into biofertility, biostimulant, and biocontrol products. Its flagship biofertility product, TerraSante™, is registered, organically certified, and commercially available in California and other U.S. states. Beyond North America, MustGrow is collaborating with Bayer AG across Europe, the Middle East, and Africa. The company holds approximately 110 issued and pending patents and reports approximately 70.4 million common shares issued and outstanding, with approximately 93.0 million shares on a fully diluted basis. The immediate share price impact was not clear from available public information.